• +353-1-415-1241(GMT OFFICE HOURS)
  • 1-800-526-8630(US/CAN TOLL FREE)
  • 1-917-300-0470(EST OFFICE HOURS)
Opioids Market to 2018 - Increasing Concentration of Abuse-Resistant Branded Generics Alter Competitive Dynamics in this Flat Market - Product Image

Opioids Market to 2018 - Increasing Concentration of Abuse-Resistant Branded Generics Alter Competitive Dynamics in this Flat Market

  • Published: January 2013
  • Region: Global
  • 43 Pages
  • GBI Research

Leading business intelligence provider GBI Research has released its latest research report, entitled “Opioids Market to 2018 - Increasing Concentration of Abuse-Resistant Branded Generics Alter Competitive Dynamics in this Flat Market”. The current opioids market is characterized by a very broad and highly diversified product portfolio. Patients experiencing moderate to severe pain for a range of underlying physiological reasons are virtually exclusively treated with opioid analgesics.

As a result, most patient populations experiencing more severe levels of pain across most pain indications, with the exception of, for example, migraines, are heavily dominated by opioids. As a therapeutic drug class, opioids have virtually no competition from molecules with non-opioid receptor targets. However, although the competition is virtually exclusively limited to opioid compounds, the current environment within this therapeutic class is highly competitive and strongly diversified.

The approved drugs are based on 16 different opioid compounds and are differentiated on a range of characteristics, which include dosage, route of administration and pharmacokinetic features, READ MORE >

1.1 List of Tables
1.2 List of Figures

2 Introduction
2.1 Introduction
2.1.1 High Levels of Product Diversification in a Highly Competitive Market Environment
2.1.2 Inconsistent Clinician Prescribing Preferences
2.1.3 Ongoing Market Shift Towards Abuse-Resistant Product Formulations
2.1.4 Increasingly Vocal Physician Associations Raise Concerns About Extent of Opioid Abuse
2.1.5 Full Commercial Potential of Transdermal Patches May Have Yet to be Fully Exploited

3 Overview of Currently Marketed Products
3.1 Major Marketed Products
3.1.1 Oxycontin
3.1.2 Exalgo
3.1.3 Onsolis
3.1.4 Duragesic
3.1.5 Opana ER
3.1.6 Vicodin CR
3.1.7 Dolophine Hydrochloride
3.1.8 Oxecta
3.1.9 Actiq
3.1.10 Embeda
3.1.11 Kadian
3.1.12 Avinza
3.2 Market Drivers and Barriers
3.2.1 Drivers
3.2.2 Barriers

4 Pipeline Analysis
4.1 Introduction
4.2 Opioid Compounds in the Developmental Pipeline
4.3 Distribution by Route of Administration
4.4 Promising Pipeline Products
4.4.1 ARX-01, AcelRX Pharmaceuticals
4.4.2 ALO-02, Pfizer
4.4.3 Zohydro ER, Zogenix
4.4.4 ELI-216, Elite Pharmaceuticals
4.4.5 BEMA Buprenorphine
4.4.6 CEP-33237, Cephalon

5 Deals Analysis
5.1 Overview:
5.1.1 M&As by Year
5.1.2 M&As by Value
5.1.3 Major M&As
5.2 Licensing Agreements
5.2.1 Licensing Agreements by Year
5.2.2 Licensing Agreements by Value
5.2.3 Major Licensing Agreements
5.3 Co-Development Agreements
5.3.1 Deals by Year
5.3.2 Major Co-Development Deals

6 Appendix
6.1 Abbreviations
6.2 Bibliography
6.3 Research Methodology
6.3.1 Coverage
6.3.2 Secondary Research
6.3.3 Primary Research
6.3.4 Pipeline Analysis
6.3.5 Expert Panel Validation
6.4 Contact Us
6.5 Disclaimer

1.1 List of Tables

Table 1: Opioids Market, Global, R&D Pipeline Analysis by Phase, 2012

1.2 List of Figures

Figure 1: Opioids Market, Drivers and Barriers, 2012
Figure 2: Opioids Market, Global, R&D Pipeline by Phase (%), 2012
Figure 3: Opioids Market, Pipeline Analysis,,Opioid Compounds in Phase III
Figure 4: Opioids Market, Pipeline Analysis,,Opioid Compounds in Phase II
Figure 5: Opioids Market, Pipeline Analysis,,Opioid Compounds in Phase I
Figure 6: Opioids Market, Pipeline Analysis, Route of Administration for Pipeline Molecules Currently in Phase III
Figure 7: Opioids Market, Pipeline Analysis, Route of Administration for Pipeline Molecules Currently in Phase II
Figure 8: Opioids Market, Pipeline Analysis, Route of Administration for Pipeline Molecules Currently in Phase I
Figure 9: Opioids Market, M&As by Year, 2005–2012
Figure 10: Opioids Market, M&As by Value ($m), 2005–2012
Figure 11: Opioids Market, Licensing Agreements by Year, 2005–2012
Figure 12: Opioids Market, Licensing Agreements by Value ($m), 2005–2012
Figure 13: Opioids Market, Co-Development Agreements by Year, 2005–2012

- Oxycontin
- Exalgo
- Onsolis
- Duragesic
- Opana ER
- Vicodin CR
- Dolophine Hydrochloride
- Oxecta
- Actiq
- Embeda
- Kadian
- Avinza

Note: Product cover images may vary from those shown

RELATED PRODUCTS

Our Clients

Our clients' logos